

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
www.sunpharma.com
CIN : L24230GJ1993PLC019050



February 16, 2017

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.
NSE Code – SUNPHARMA

BSE Ltd,
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001.
BSE Code – 524715

Sub: Clarification /Information on news item

Dear Sirs,

With reference to your letter and email dated February 16, 2017 referring to recent news item appeared on CNBC TV18 dated February 16, 2017 captioned "UK Regulator approves Sun Pharma's Generic drug of Tobramycin", we hereby submit our response as follows:

There is no information under regulation 30 that has not been announced to the Exchanges which could explain the movement in the trading.

Please further note that the approval for the aforesaid product, received by one of our wholly owned subsidiary companies, is not from UK regulator but from European Medicines Agency. However this is not a material development for the Company. Sun Pharma and its subsidiaries continue to file multiple products across multiple countries globally on an on-going basis. As and when there are material developments, we will make the required disclosures.

Kindly let us know in case you require any further clarification.

Yours faithfully,

For Sun Pharmaceutical Industries Limited,


Ashok I Bhuta
Compliance Officer